Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines

Paul Guedeney and Jean-Philippe Collet *
Institut de Cardiologie, Sorbonne Université, ACTION Study Group, INSERM UMRS_1166, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), 75013 Paris, France; pguedeney@hotmail.fr
* Correspondence: jean-philippe.collet@aphp.fr

Received: 4 October 2020; Accepted: 26 October 2020; Published: 28 October 2020

Abstract: The management of acute coronary syndrome (ACS) has been at the center of an impressive amount of research leading to a significant improvement in outcomes over the last 50 years. The 2020 European Society of Cardiology (ESC) Guidelines for the management of patients presenting without persistent ST-segment elevation myocardial infarction have incorporated the most recent breakthroughs and updates from large randomized controlled trials (RCT) on the diagnosis and management of this disease. The purpose of the present review is to describe the main novelties and the rationale behind these recommendations. Hence, we describe the accumulating evidence against P2Y12 receptors inhibitors pretreatment prior to coronary angiography, the preference for prasugrel as leading P2Y12 inhibitors in the setting of ACS, and the numerous available antithrombotic regimens based on various durations of dual or triple antithrombotic therapy, according to the patient ischemic and bleeding risk profiles. We also detail the recently implemented 0 h/1 h and 0 h/2 h rule in, rule out algorithms and the growing role of computed coronary tomography angiography to rule out ACS in patients at low-to-moderate risk.

Keywords: acute coronary syndrome; oral anticoagulation; antiplatelet; percutaneous coronary intervention

1. Introduction

Despite tremendous achievements in its management, coronary artery disease (CAD) remains a leading cause of mortality worldwide [1,2]. Acute coronary syndrome, the most severe manifestation of CAD, is burdened by a significant mortality, concerning approximately 5%–8% of the cases within six months of diagnosis [3]. To further improve outcomes following acute coronary syndrome (ACS), it is paramount for physicians dealing with such patients to implement in clinical practice the latest findings from large RCTs. The purpose of the ESC guidelines is to summarize and evaluate available evidence to facilitate decision making processes and to propose the best management of patients according to their specific situations and potential comorbidities. This year, the ESC updated their guidelines with respect to the diagnosis and management of patients presenting with non-ST-segment-elevation ACS (NSTE-ACS) [4,5]. The purpose of the present review is to summarize the main novelties of these guidelines and detailed the evidence and data that led to these updates.

2. Diagnosis of Acute Coronary Syndrome

2.1. Rule-In, Rule-Out Algorithms

Measurement of cardiac troponin (cTn) T or I is mandatory for the diagnosis and risk stratification of an ACS. Over the last decade, use of high-sensitivity (Hs) assays has considerably grown in clinical
practice, allowing for more rapid detection of troponin elevation, within one hour of symptom onset, and with improved sensibility and specificity [5]. Based on the rational that Hs-cTn is a continuous variable with early (i.e., within 1 h or 2 h) absolute changes being surrogate of later (within 3 h or 6 h) absolute changes, the 2015 ESC guidelines recommended to use rapid rule-out and rule-in protocols. The ESC 0 h/1 h algorithm is based on a blood sample at 0 h and 1 h thereafter, using validated thresholds for both baseline and variation (i.e., ΔhS-cTn) levels of hs-cTn (Figure 1A,B).

Figure 1. Rule in/Rule out algorithms according to the 2020 ESC NSTEMI guidelines: 0 h/1 h algorithm (A) and 0 h/2 h algorithm (B). STE-ACS: non-ST-segment elevation myocardial infarction; cTn: cardiac troponin; CCTA: coronary computed tomography angiography.

The 2020 ESC Non-ST-segment elevation Myocardial infarction (NSTEMI) guidelines have extended these recommendations to include validated 0 h/2 h algorithms, following recent publications (Figure 1B) [6–8]. Conversely, the more historical ESC 0 h/3 h algorithm was demoted from a class I recommendation to a class IIa, following the results of 3 larges diagnosis studies which suggested that the ESC 0 h/1 h algorithms were associated with improved safety and efficacy [9–11]. In case of ruled-out-patients, or patients for whom electrocardiogram or hs-cTn dosage may be inconclusive,
coronary computed tomography angiogram (CCTA) may be readily performed as an alternative to invasive coronary angiography to exclude ACS (class I recommendations, level A of evidence) [5]. In a recent study, 207 patients presenting with acute chest pain, elevated hs-cTn and inconclusive electrocardiogram were randomized to a strategy cardiovascular magnetic resonance imaging or CCTA-first versus standard of care [12]. While all patients randomized to the standard of care underwent coronary angiogram, only 67% of the patient randomized to CCTA-first underwent such exam (p < 0.001), without significant difference in term of major adverse cardiac events at one year. Moreover, a subanalysis of the very Early Versus Deferred Invasive Evaluation Using Computerized Tomography in Patients with Acute Coronary Syndromes (VERDICT) trial has confirmed the very high negative predictive value of CCTA [13]. In this study, CCTA was performed prior to coronary angiogram in 1023 patients and was associated with negative predictive value of 90.9%, 95% confidence interval (CI) 86.8–94.1%, with a sensitivity and specificity of 96.5%, 95% CI 94.9–97.8%, and 72.4%, 95% CI 67.2–77.1%, respectively.

2.2. Other Biomarkers

B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) may be useful for the diagnosis and evaluation of the severity of heart failure in the setting of ACS [14,15]. Systematic assessment of other biomarkers, such as C-reactive protein or copeptin, though associated with outcomes following ACS, is no longer recommended as their prognosis value compared to BNP/NT-proBNP or the Global registry of Acute Coronary Events (GRACE) score remains limited [16–18].

3. Management of The Antithrombotic Treatment

3.1. The Issue of Pretreatment

Pretreatment refers to the administration of aspirin and P2Y12 receptor inhibitors prior to the coronary angiogram [19]. The rationale behind pretreatment is ensuring an adequate platelet inhibition as fast as possible once the diagnosis of ACS is suspected. Pharmacological studies have indeed demonstrated that several hours may be necessary for the achievement of sufficient platelet inhibition following oral administration of a loading dose, even when using potent P2Y12 inhibitors such as prasugrel or ticagrelor [20]. Notwithstanding, pretreatment may expose patients to an unnecessary risk of bleeding if the diagnosis of ACS is eventually disproved following coronary angiogram, which may be the case in up to 35% of patients [21]. Until recently, large RCT evaluating the safety and efficacy of pretreatment in the setting of ACS have been scarce. The largest RCT on this topic has been the Comparison of prasugrel at the Time of Percutaneous Coronary Intervention (PCI) or as Pretreatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction (ACCOAST) trial which compared a strategy of systematic prasugrel pretreatment with a 30 mg loading dose followed by an additional 30 mg of prasugrel in case of PCI to a strategy of 60 mg loading dose of prasugrel only in case of PCI [21] in NSTEMI patients. In this trial, the pretreatment strategy did not impact the rate of the composite endpoint of death from cardiovascular causes, myocardial infarction (MI), stroke, urgent revascularization or glycoprotein IIb/IIIa inhibitor bailout within 7 days (Hazard ratio[HR] 1.02, 95%CI 0.84–1.25, p = 0.81, but it significantly increased the risk of Thrombolysis in Myocardial Infarction (TIMI) life-threatening and major bleeding not related to coronary artery bypass grafting (CABG) (HR 5.56 95%CI 1.63–19.0 and HR 2.95, 95% CI 1.39–6.28, respectively). These findings were further confirmed in the PCI-only cohort and were not impacted by the timing of angiography, when performed within the first 48 h of randomization [22,23]. Following the ACCOAST trial, the ESC guidelines have recommended against pretreatment, but only with prasugrel, and without specific recommendations for pretreatment with ticagrelor. This distinction was likely the consequence of the Platelet Inhibition and Patient Outcomes (PLATO) trial, which included patients presenting with ACS and compared ticagrelor to clopidogrel, which were both administered following randomization and prior to coronary angiogram [24]. In a post-hoc analysis of the PLATO trial, only including patients presenting with
NSTEMI, treatment with ticagrelor was associated with a reduction of cardiovascular death, MI, or stroke and all-cause death, with no significant increase of major bleeding within the first 10 days of randomization, and regardless of whether patients underwent revascularization or not [25]. It is important to note however, that pretreatment was applied to both ticagrelor and clopidogrel and was not the subject of randomization.

The debate on this topic has nonetheless been settled with the recent publication of several trials directly evaluating the safety and efficacy of pretreatment. First, the Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 was an open-labeled trial which included 4018 patients presenting with an ACS and scheduled to undergo coronary angiography [26]. The trial compared a strategy of systematic pretreatment with ticagrelor to a strategy with prasugrel where the loading dose was only administered in case of PCI unless patients were presenting with STEMI. In this trial, treatment with ticagrelor and systematic pre-treatment was associated with a significant increase of the risk of death, MI, or stroke at one year (HR 1.36 95% CI 1.09–1.70), demonstrating that a more rapid onset of platelet inhibition did not result into long term clinical benefit. These results were further confirmed by the recently published downstream versus upstream administration of P2Y_12 receptor blockers in non-ST elevated acute coronary syndromes with initial invasive indication (DUBIUS) trial [27]. The DUBIUS trial was an open-label study where patients presenting with NSTEMI and planned to undergo coronary angiography were randomized to an upstream strategy based with ticagrelor pretreatment or downstream strategy based on either ticagrelor or prasugrel, solely administered in case of PCI. The trial was prematurely interrupted for futility after the inclusion of 1449 patients. There was no significant difference between the two strategies with respect to the composite endpoint of death due to vascular cause, MI, stroke, or Bleeding Academic Research Criteria (BARC) type 3, 4, or 5 bleeding as well as each individual endpoint. These data from randomized trials have been confirmed by large real-world registries. The ARIAM-Andalucía registry retrospectively evaluated 9621 patients presenting with ACS and managed invasively [28]. The study, stratified according to the type of ACS, reported a statistically significant benefit for pretreatment with clopidogrel in case of STEMI, with lower risk of reinfarction (Odds Ratio [OR] 0.53 95%CI 0.27–0.96), stent thrombosis (OR 0.67 95%CI 0.48–0.94) and mortality (OR 0.67 95%CI 0.48–0.94). Interestingly, the benefits of pretreatment were no longer present when evaluating patients presenting with NSTE-ACS. More recently, a study from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) evaluated 64,857 patients undergoing PCI for NSTEMI from 2010 to 2018, the vast majority of whom (i.e., 92.4%) were pretreated, mostly with ticagrelor [29]. In this study, pretreatment did not result in improved survival at one month (OR 1.17 95%CI 0.66–2.11) or one year (OR 1.34 95%CI 0.77–2.34), nor did it significantly reduce the risk of stent thrombosis at 30 days (OR 0.81 95%CI 0.42–1.55). However, pretreatment resulted in increased risk of in-hospital bleeding (OR 1.49% 95%CI 1.06–2.12). Following this accumulation of evidence demonstrating the lack of benefit in terms of ischemic prevention with a consistent increase of the risk of bleeding complications associated with pretreatment, the 2020 ESC NSTEMI guidelines have recommended against the routine administration of P2Y_12 inhibitors in patients in whom coronary artery anatomy is not known and an early invasive management is planned (Figure 2) [5].

However, the door is left open and “Pre-treatment with P2Y_12 inhibitors may be considered (class IIb) in patients with NSTEMI who are not planned to undergo an early invasive strategy and are not at high risk of bleeding”.

was associated with maintained anti-ischemic efficacy compared to the one-size-fit-all ticagrelor-based strategy, while protecting these frail patients against excess risk for bleeding [31]. The physiological explanation behind the improved performance of prasugrel over ticagrelor remained to be better understood, as both agents lead to consistent platelet inhibition [20]. A recent small randomized trial reported prasugrel to be associated with improved endothelial function, as measured by the endothelium-dependent flow-mediated dilation of the radial artery following stenting, and reduced inflammation as measured by interleukin-6 level over ticagrelor or clopidogrel [32]. Ticagrelor may also induce dyspnea which may lead to increased risk of medication discontinuation [24]. According to the 2020 ESC NSTEMI guidelines, prasugrel should be considered (class IIa) in preference to ticagrelor for patients undergoing PCI for ACS without ST segment elevation [5].

### 3.2. What P2Y12 Receptors Inhibitors Should Be Used?

A personalized approach has been chosen in these guidelines to offer all possibilities according to the patient risk. When the bleeding risk is very high (i.e., planned surgery and presence of one major criteria of the Academic Research Consortium for High Bleeding Risk [ARC-HBR] or PRECISE-DAPT score ≥ 25) or high (one major criteria of the ARC-HBR or PRECISE-DAPT score ≥ 25), clopidogrel should be the preferred choice with a shorter dual antiplatelet therapy (DAPT) duration of one and three months, respectively.

When the bleeding risk is qualified as standard, the choice must be made between ticagrelor and prasugrel. Since the landmark PLATO and therapeutic outcomes by optimizing platelet inhibition with Prasugrel-thrombolysis in myocardial infarction 38 (TRITON-TIMI 38) trials, use of DAPT based on the association of aspirin with a potent P2Y12 receptors inhibitors (i.e., ticagrelor or prasugrel) has been the cornerstone of the antithrombotic treatment for patients presenting with ACS [24,30]. Whether or not one of these two agents should be preferably used in the setting of ACS has remained an open debate until recently. In the ISAR-REACT 5 trial, treatment with prasugrel compared to ticagrelor was associated with a significant reduction of the primary endpoint, mainly driven by the reduction of the risk of reinfarction (HR 0.61 95% CI 0.44–0.85), without any significant difference in term of BARC type 3, 4, or 5 bleeding (HR 0.89 95% CI 0.66–1.20) [26]. In this trial, a reduced maintenance dose of 5 mg daily was used in patients aged over 75 years of with body weight <60 kg. In the dedicated substudy, which included 27.4% of the overall population, this individualized regimen of prasugrel was associated with maintained anti-ischemic efficacy compared to the one-size-fit-all ticagrelor-based strategy, while protecting these frail patients against excess risk for bleeding [31]. The physiological explanation behind the improved performance of prasugrel over ticagrelor remained to be better understood, as both agents lead to consistent platelet inhibition [20].

In the ISAR-REACT 5 trial, treatment with prasugrel compared to ticagrelor was associated with a significant reduction of the primary endpoint, mainly driven by the reduction of the risk of reinfarction (HR 0.61 95% CI 0.44–0.85), without any significant difference in term of BARC type 3, 4, or 5 bleeding (HR 0.89 95% CI 0.66–1.20) [26]. In this trial, a reduced maintenance dose of 5 mg daily was used in patients aged over 75 years of with body weight <60 kg. In the dedicated substudy, which included 27.4% of the overall population, this individualized regimen of prasugrel was associated with maintained anti-ischemic efficacy compared to the one-size-fit-all ticagrelor-based strategy, while protecting these frail patients against excess risk for bleeding [31]. The physiological explanation behind the improved performance of prasugrel over ticagrelor remained to be better understood, as both agents lead to consistent platelet inhibition [20]. A recent small randomized trial reported prasugrel to be associated with improved endothelial function, as measured by the endothelium-dependent flow-mediated dilation of the radial artery following stenting, and reduced inflammation as measured by interleukin-6 level over ticagrelor or clopidogrel [32]. Ticagrelor may also induce dyspnea which may lead to increased risk of medication discontinuation [24]. According to the 2020 ESC NSTEMI guidelines, prasugrel should be considered (class IIa) in preference to ticagrelor for patients undergoing PCI for ACS without ST segment elevation [5].

**Figure 2.** Pretreatment with P2Y12 receptors inhibitors in patients presenting with non-ST-segment elevation myocardial infarction. NSTE-ACS: non-ST-segment elevation myocardial infarction; ESC: European society of Cardiology.
3.3. What Antithrombotic Regimen Following PCI?

The implementation of newer generation drug-eluting, and the generalization of potent $\text{P}_2\text{Y}_{12}$ inhibitors receptors as well as lipid-lowering medication have led to a reduction of the risk of stent thrombosis and non-stent related myocardial infarction following PCI [33–38]. As a result, the benefit of sustained DAPT may translate into smaller absolute ischemic event risk reduction, potentially outweighed by the associated increased risk of bleeding [39]. Based on the rational that aspirin may add only limited platelet inhibition when associated to potent $\text{P}_2\text{Y}_{12}$ inhibitors, several large RCT have evaluated the safety and efficacy or early aspirin discontinuation, after 1 to 3 months of DAPT, with potent $\text{P}_2\text{Y}_{12}$ inhibitors monotherapy prolongation [40–47].

In particular, the Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention (TWILIGHT) trial randomized 7119 patients undergoing PCI, a majority of whom (i.e., 65%) for NSTEMI or unstable angina, and presenting with at least one clinical feature of high ischemic or bleeding risk and one angiographic feature of high-risk lesion to a strategy of ticagrelor monotherapy following three months of uncomplicated DAPT or prolonged DAPT [45]. The trial found ticagrelor monotherapy to be associated with a reduction of BARC type 2, 3, or 5 bleeding (4.0% vs. 7.1% HR 0.56 95%CI 0.45–0.68), without any significant difference with respect to ischemic event.

If the TWILIGHT regimen may not be applied, patients should be treated with a 12-month duration DAPT including prasugrel or ticagrelor especially when there are high thrombotic risk criteria. However, when facing cases of patients deemed unsuitable for potent platelet inhibition, it is also possible to consider guided de-escalation of $\text{P}_2\text{Y}_{12}$ inhibitors receptors, which corresponds to switching from a potent $\text{P}_2\text{Y}_{12}$ inhibitors (i.e., prasugrel or ticagrelor) down to clopidogrel [48]. Such de-escalation should be guided by the results of platelet function testing, as in the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet treatment for Acute Coronary Syndromes (TROPICAL-ACS) trial, or on the results of CYP2C19-directed genotyping, which was evaluated in the Patients Outcomes after Primary PCI (POPular Genetics) trial [49–51]. The POPular Genetic trial, in particular, included 2488 patients undergoing PCI for STEMI reported a reduced risk of major bleeding with the genotyping-guided strategy compared to standard DAPT with ticagrelor or prasugrel (HR 0.78 95%CI 0.61–0.98) and a number needed to treat to prevent one Platelet Inhibition and Patient Outcomes (PLATO) major or minor bleeding of 37, without any significant offset in term of ischemic events [50].

Extended dual antithrombotic or antiplatelet regimen may be considered in case of high-risk of ischemic event with no high risk of bleeding [52]. Several regimen may then be considered based on the results of the Prevention of Cardiovascular events in Patients With Prior heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction (PEGASUS-TIMI 54), the Cardiovascular Outcomes for People Using Anticoagulant Strategies (COMPASS) and the Dual Antiplatelet Therapy (DAPT) trials (Figure 3). The main findings of these trials, along with the evaluated antithrombotic regimen are summarized in Table 1.

3.4. Risk Stratification

The integration of the bleeding and ischemic risks of patients undergoing PCI for an ACS is paramount as it directly impacts the type and duration of the antithrombotic regimen. The various clinical criteria previously associated with a high risk of ischemic complication following ACS are summarized in the Table 2.

According to the 2020 ESC NSTEMI guidelines, an extended long-term secondary prevention with the addition of a second antithrombotic agent (i.e., antiplatelet or anticoagulant) to aspirin should be considered in case of high thrombotic risk (class IIa) and may be considered in case of moderate thrombotic risk (class IIb) [5].
Figure 3. Antithrombotic regimen following PCI for NSTE-ACS according to the 2020 ESC NSTEMI guidelines. NSTE-ACS: non-ST-segment-elevation acute coronary syndrome; ESC: European society of Cardiology; (N)OAC: (non-vitamin K antagonist) oral anticoagulant; DAPT: dual antiplatelet therapy.
Table 1. Main trials evaluating prolonged antithrombotic regimen following PCI.

| Trial         | Year of Publication | Main Inclusion Criteria                                                                 | Proportion of Patient with ACS | Evaluated Antithrombotic Regimen                                                                 | Main Results                                                                                                                                                                                                                     | Number Needed to Treat (Ischemic Outcomes) | Number Needed to Harm (Bleeding Outcomes) |
|---------------|---------------------|----------------------------------------------------------------------------------------|--------------------------------|----------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|------------------------------------------|
| DAPT [53]     | 2014                | PCI followed by uncomplicated 12-month DAPT                                              | 4251/9961 (42.7%)             | Prolonged DAPT with aspirin and clopidogrel (65.2%) or prasugrel (34.8%) for 18 months | Prolonged DAPT reduced ST (HR 0.29 95% CI 0.17–0.48) and MACE (HR 0.71 95% CI 0.59–0.85) with increased risk of moderate or severe bleeding | 63                                       | 105                                      |
| PEGASUS       | 2015                | - Prior MI within 1 to 3 years                                                           | 21162/21162 (100%) including 3499/21162 (16.6%) patients with multiple prior MI | Prolonged DAPT with aspirin and ticagrelor (60 mg twice daily or 90 mg twice daily) | Both regimens of prolonged DAPT with ticagrelor reduced the risk of CV death, MI or stroke (HR 0.85 95% CI 0.75–0.96 for 90 mg b.i.d. and HR 0.84 95% CI 0.74–0.95 for 60 mg b.i.d.) and increased the risk of TIMI major bleeding (HR 2.69 95% CI 1.96–3.70 for 90 mg b.i.d. and HR 2.32 95% CI 1.68–3.21 for 60 mg b.i.d.) | 84 for ticagrelor 90 mg b.i.d. 79 for ticagrelor 60 mg b.i.d. | 65 for ticagrelor 90 mg b.i.d. 81 for ticagrelor 60 mg b.i.d. |
| TIMI 54 [54]  | 2017                | - Established coronary and/or peripheral artery disease - If coronary disease and age <65 years then at least one of the following: ≥2 vascular bed disease, ≥2 risk factors among: diabetes mellitus, current smoking, chronic kidney disease, heart failure, or prior stroke| 17028/27395 (62.2%) patients with prior MI | Prolonged rivaroxaban 2.5 twice daily and aspirin (100 mg once daily) or rivaroxaban (5 mg twice a day) monotherapy | DAT with rivaroxaban + aspirin was associated with a reduction of CV death, MI or stroke (HR 0.76 95% CI 0.66–0.86) but not rivaroxaban alone (HR 0.90 95% CI 0.79–1.03). Both regimens increased the risk of major bleeding (HR 1.70 95% CI 1.40–2.05 for rivaroxaban + aspirin and HR1.51 95% CI 1.25–1.84 for rivaroxaban alone) | 77 for rivaroxaban + aspirin 84 for rivaroxaban + aspirin |                                              |                                           |

DAPT: Dual antiplatelet therapy; ST: stent thrombosis; HR: hazard ratio; CI: confidence interval; MACE: major adverse cardiac and cerebrovascular event; TIMI: Thrombolysis In Myocardial Infarction; MI: myocardial infarction; PCI: percutaneous coronary intervention. ACS: acute coronary syndrome; CV: cardiovascular.
Table 2. Thrombotic risk factors according to the 2020 ESC NSTEMI guidelines.

| Risk Category | Complex Coronary Lesion and/or Percutaneous Procedure | High Thrombotic Risk | Moderate Thrombotic Risk |
|---------------|--------------------------------------------------|----------------------|--------------------------|
| Criteria      | - ≥3 stents implanted or total stent length ≥ 60 mm | AND at least 1 of the following: | - Non-complex coronary disease or procedure AND at least 1 of the following: |
|               | - ≥3 lesions treated                               | - DM requiring medication | - DM requiring medication |
|               | - Critical localization: left main, last patent vessel | - Recurrent MI | - Recurrent MI |
|               | - High-risk procedure: bifurcation, stenting with ≥2 stents or chronic total occlusion | - Polyvascular disease (CAD and peripheral disease) | - Polyvascular disease (CAD or peripheral disease) |
|               | - History of stent thrombosis on antiplatelet therapy | - Premature (<45 years) or accelerated (new lesion within 2 years of the index procedure) CAD | - CKD (eGFR between 15 and 59 mL/min/m²) |
|               |                                                  | - Concomitant systemic inflammatory disease- |                                  |
|               |                                                  | - CKD (eGFR between 15 and 59 mL/min/m²) |                                  |

CAD: coronary artery disease; ESC: European Society of cardiology; DM: diabetes mellitus; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; MI: myocardial infarction.
However, extended duration of dual antithrombotic therapy (DAT) should only be considered in the absence of high risk of bleeding. Recently, a consensus definition of high bleeding risk profile was proposed with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) (Table 3) [56].

**Table 3. Academic Research Consortium for High Bleeding risk.**

| High Bleeding Risk: ≥ 1 Major Criterion or ≥2 Minor Criteria |
|---|
| **Major Criteria** |
| Chronic Oral Anticoagulation |
| Hemoglobin < 11 g/dL |
| Severe or End-Stage Chronic Kidney Disease |
| Moderate or severe thrombocytopenia (<100 × 10⁹/L) |
| Chronic Bleeding Diathesis |
| Liver Cirrhosis with Portal Hypertension |
| Active Malignancy |
| Any History of Spontaneous Intracranial Hemorrhage or Brain Arteriovenous Malformation or Previous Traumatic Intracranial Hemorrhage Within the Past 12 Months |
| Nondeferrable Major Surgery on Dual Antiplatelet Therapy |
| Recent Major Surgery or Major Trauma Within 30 Days of Percutaneous Coronary Intervention |
| **Minor Criteria** |
| Age ≥ 75 Years |
| Moderate Chronic Kidney Disease |
| Hemoglobin 11–12.9 g/dL for Men and 11–11.9 g/dL for Women |
| Spontaneous Bleeding Requiring Hospitalization of Transfusion Within the Past 12 Months |
| Long-Term Use of Oral Non-Steroidal Anti-Inflammatory |
| History (>1 years ago) of ischemic stroke |

This pragmatic score was validated on an independent contemporary cohort, approximately half of which included patients presenting with ACS [57]. This score was introduced in the 2020 ESC NSTEMI guidelines as potential guidance tool to refine bleeding stratification, with a better sensitivity than the PRECISE-DAPT score.

### 3.5. Pairing Chronic Oral Anticoagulation with Antiplatelet Therapy

With respect to patient requiring long-term oral anticoagulant, several large RCT including a majority of patients presenting with an ACS, evaluated DAT regimen based on non-vitamin K antagonist oral anticoagulant (NOAC) + P2Y₁₂ versus triple antithrombotic therapy (TAT) with vitamin K antagonist (VKA) + aspirin + P2Y₁₂ receptor inhibitors and demonstrated a significant reduction of the risk of bleeding complication with the former (Table 4) [58–65].

The meta-analyses of these trials have confirmed the significant reduction of bleeding and did not report any significant increase in term of ischemic event, although MI or stent thrombosis were numerically higher with DAT compare to TAT [46,66]. Consequent to this accumulation of data, the 2020 ESC NSTEMI guidelines have recommended to use a short duration of TAT (i.e., in-hospital or up to one week following PCI) in this high risk population, unless the patients also present a significant risk of ischemic risk event, and to promptly relay TAT with DAT based on the association of NOAC and P2Y₁₂ inhibitors for 6–12 months according to the bleeding risk (Figure 2) [5]. Following the results of the Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial, it is no longer recommended to prolonged DAT more than one year after PCI in stable patients. Indeed, the AFIRE trial randomized 2236 patients with atrial fibrillation who had undergone PCI or CABG more than one year earlier to DAT with rivaroxaban (or VKA) and a single antiplatelet agent to rivaroxaban alone [67]. The strategy of oral anticoagulant monotherapy was associated with a significant reduction of the risk of major bleeding (HR 0.59 95%CI 0.39–0.89) as well as the composite of death, stroke, MI, systemic embolism, or unstable angina (HR 0.72 95%CI 0.55–0.95).
Table 4. Main trials evaluating dual and triple antithrombotic regiment following PCI in patients with long-term indication for chronic oral anticoagulant.

| Trial          | Years of Publication | Main Inclusion Criteria                                      | Proportion of Patient Presenting with ACS | Antithrombotic Regimen Evaluated                                      | Main Results                                                                 | Number Needed to Prevent One Ischemic Outcome | Number Needed to Prevent One Bleeding Outcome |
|---------------|----------------------|--------------------------------------------------------------|------------------------------------------|-----------------------------------------------------------------------|----------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| WOEST [58]    | 2013                 | Indication for Oral Anticoagulation and PCI                  | 155/563 (27.5%)                          | DAT (Clopidogrel + VKA) vs. TAT (Aspirin + Clopidogrel + VKA)          | Reduced Risk of Bleeding with DAT (HR 0.36 95% CI 0.26–0.50) And MACE (HR 0.60 95% CI 0.38–0.94) | 15                                                                 | 4 (For Any Bleeding) 42 (For TIMI Major Bleeding) |
| PIONEER AF-PCI [59] | 2016              | Non-valvular AF and PCI with coronary stent implantation     | 1096/2124 (51.6%)                        | DAT With Rivaroxaban (15 mg Once Daily) + P2Y12 Inhibitors and TAT With Rivaroxaban (2.5 mg Twice Daily) + Aspirin + Clopidogrel Or VKA + Aspirin + Clopidogrel | DAT Was Associated with Reduced Risk of Clinically Significant Bleeding (HR 0.59 95% CI 0.47–0.76) Vs. TAT with VKA + Aspirin, Without Significant Difference in Term of Ischemic Events | -                                                                 | 10                                                                 |
| RE-DUAL PCI [60] | 2017               | Non valvular AF Successful PCI < 120 h                       | 2007/2725 (73.7%)                        | TAT With Dabigatran (110 mg Twice Daily Or 150 mg Twice Daily) + P2Y12 Inhibitors Vs. TAT with VKA + Aspirin+ P2Y12 Inhibitors | Both Regimens of DAT Were Associated with Reduced Risk of ISTH Major Or Clinically Relevant Bleeding (110 mg B.I.D. HR 0.52 95% CI 0.42–0.63 And 150 mg B.I.D. HR 0.72 95% CI 0.58–0.88) | -                                                                 | 9 For Dabigatran 110 mg Twice Daily And 18 For 150 mg Twice Daily |
| AUGUSTUS [61] | 2019                | AF and recent PCI or ACS with planned used of at least 6 months of P2Y12 | 2811/4614 (60.9%)                       | TAT With Apixaban or VKA Vs. DAT With Apixaban Or VKA +Aspirin+P2Y12 Inhibitors | DAT Was Associated with Reduced Risk of ISTH Major Or Clinically Relevant Bleeding (HR 0.53 95% CI 0.45–0.63) Without Significant Difference In Term Of Ischemic Events | -                                                                 | 14                                                                 |
| ENTRUST-AF PCI [62] | 2019              | Non valvular AF and PCI procedure for stable CAD or ACS      | 777/1506 (51.6%)                         | DAT With Edoxaban 60 Mg Twice Daily +P2Y12 Inhibitor or TAT With VKA+Aspirin+P2Y12 Inhibitors | DAT Was Not Significantly Associated with Reduced Risk of ISTH Major Or Clinically Relevant Bleeding (HR 0.83 95% CI 0.65–1.05) Without Significant Difference For Ischemic Events | -                                                                 | -                                                                 |

DAT: dual antithrombotic therapy; TAT: Triple antithrombotic therapy; VKA: vitamin K antagonist; ISTH International Society of Thrombosis and haemostasis; AF: atrial fibrillation; PCI: percutaneous coronary intervention; TIMI: Thrombolysis in Myocardial Infarction.
4. Conclusions

The diagnosis and management of ACS remain fast-evolving fields, following the latest results from large RCTs. Antithrombotic management of ACS have known significant changes with prasugrel becoming the preferred P2Y_{12} inhibitors while pretreatment with any P2Y_{12} inhibitors is henceforth contraindicated with patients planned to undergo rapid coronary angiography. Following the acute event, antithrombotic treatment can be individualized to the ischemic and bleeding risk profiles of each patient, with numerous available regimens based on more or less prolonged triple or dual antithrombotic therapy.

Author Contributions: J.-P.C. conceptualized and supervised the manuscript and made critical edits to. P.G. wrote the first draft of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: Jean-Philippe Collet has received research grants or honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly, Fédération Française de Cardiologie, Lead-Up, Medtronic, Merck Sharp & Dohme, Sanofi, Servier, and WebM.

References

1. Roth, G.A.; Johnson, C.; Abajobir, A.; Abd-Allah, F.; Ahera, S.F.; Abyu, G.; Ahmed, M.; Aksut, B.; Alam, T.; Alam, K.; et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J. Am. Coll. Cardiol. 2017, 70, 1–25. [CrossRef] [PubMed]

2. Guedeney, P.; Aboyans, V.; Dalon, F.; Oksen, D.; Belhassen, M.; Nolin, M.; Briere, J.; van Ganse, E.; Montalescot, G. Epidemiology, treatment patterns and outcomes in patients with coronary or lower extremity artery disease in France. Arch. Cardiovasc. Dis. 2019, 112, 670–679. [CrossRef]

3. Puymirat, E.; Simon, T.; Cayla, G.; Cottin, Y.; Elbaz, M.; Coste, P.; Lemesle, G.; Motreff, P.; Popovic, B.; Khalife, K.; et al. Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015. Circulation 2017, 136, 1908–1919. [CrossRef] [PubMed]

4. Roffi, M.; Patrono, C.; Collet, J.-P.; Mueller, C.; Valgimigli, M.; Andreotti, F.; Bax, J.J.; Borger, M.A.; Brotons, C.; Chew, D.P.; et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society for Cardiology (ESC). Eur. Heart J. 2016, 37, 267–315. [PubMed]

5. Collet, J.-P.; Thiele, H.; Barbato, E.; Barthélémy, O.; Bauersachs, J.; Bhatt, D.L.; Dendale, P.; Dorobantu, M.; Edvardsen, T.; Folliguet, T.; et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2020, 1–79. [CrossRef]

6. Nestelberger, T.; Boeddinghaus, J.; Greenslade, J.; Parsonage, W.A.; Than, M.; Wussler, D.; Lopez-Ayala, P.; Zimmermann, T.; Meier, M.; Troester, V.; et al. Two-Hour Algorithm for Rapid Triage of Suspected Acute Myocardial Infarction Using a High-Sensitivity Cardiac Troponin I Assay. Clin. Chem. 2019, 65, 1437–1447. [CrossRef]

7. Boeddinghaus, J.; Reichlin, T.; Cullen, L.; Greenslade, J.H.; Parsonage, W.A.; Hammett, C.; Pickering, J.W.; Hawkins, T.; Aldous, S.; Twenerbold, R.; et al. Two-Hour Algorithm for Triage toward Rule-Out and Rule-In of Acute Myocardial Infarction by Use of High-Sensitivity Cardiac Troponin I Assay. Clin. Chem. 2016, 62, 494–504. [CrossRef]

8. Reichlin, T.; Cullen, L.; Parsonage, W.A.; Greenslade, J.; Twenerbold, R.; Moehring, B.; Wildi, K.; Mueller, S.; Zellweger, C.; Mosimann, T.; et al. Two-hour algorithm for triage toward rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Am. J. Med. 2015, 128, 369–379. [CrossRef]

9. Badertscher, P.; Boeddinghaus, J.; Twenerbold, R.; Nestelberger, T.; Wildi, K.; Wussler, D.; Schwarz, J.; Puelacher, C.; Rubini, G.M.; Kozhuharov, N.; et al. Direct Comparison of the 0/1h and 0/3h Algorithms for Early Rule-Out of Acute Myocardial Infarction. Circulation 2018, 137, 2536–2538. [CrossRef]

10. Chapman, A.R.; Anand, A.; Boeddinghaus, J.; Ferry, A.V.; Sandeman, D.; Adamson, P.D.; Andrews, J.; Tan, S.; Cheng, S.F.; D’Souza, M.; et al. Comparison of the Efficacy and Safety of Early Rule-Out Pathways for Acute Myocardial Infarction. Circulation 2017, 135, 1586–1596. [CrossRef]
11. Chapman, A.R.; Fujisawa, T.; Lee, K.K.; Andrews, J.P.; Anand, A.; Sandeman, D.; Ferry, A.V.; Stewart, S.; Marshall, L.; Strachan, F.E.; et al. Novel high-sensitivity cardiac troponin I assay in patients with suspected acute coronary syndrome. *Heart* 2019, 105, 616–622. [CrossRef]

12. Smulders, M.W.; Kietseelaer, B.L.J.H.; Wildberger, J.E.; Dagnelie, P.C.; Brunner-La Rocca, H.; Mingels, A.M.A.; van Cauteren, Y.J.M.; Theunissen, R.A.L.J.; Post, M.J.; Schalla, S.; et al. Initial imaging-guided strategy versus routine care in patients with non-ST-segment elevation myocardial infarction. *J. Am. Coll. Cardiol.* 2019, 74, 2466–2477. [CrossRef] [PubMed]

13. Linde, J.J.; Kelbaek, H.; Hansen, T.E.; Sigvardsen, P.E.; Torp-Pedersen, C.; Bech, J.; Heitmann, M.; Nielsen, O.W.; Høfsten, D.; Kühl, J.T.; et al. Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. *J. Am. Coll. Cardiol.* 2020, 75, 453–463. [CrossRef] [PubMed]

14. Björn, R.; Shmuel, C.; Aaron, C.; Ben-Yehuda, O.; Gersh, B.J.; Lembo, N.J.; Brown, W.M., III; Banning, A.P.; Taggart, D.P.; Serruys, P.W.; et al. B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease. *Circulation* 2018, 138, 469–478.

15. Zhang, C.; Jiang, L.; Xu, L.; Tian, J.; Liu, J.; Zhao, X.; Feng, X.; Wang, D.; Zhang, Y.; Sun, K.; et al. Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease. *Eur. Heart J.* 2019, 40, 3397–3405. [CrossRef] [PubMed]

16. Kalkman, D.N.; Aquino, M.; Claessen, B.E.; Baber, U.; Guedeney, P.; Sorrentino, S.; Vogel, B.; de Winter, R.J.; Sweeny, J.; Kovacic, J.C.; et al. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. *Eur. Heart J.* 2018, 39, 4101–4108. [CrossRef] [PubMed]

17. Guedeney, P.; Claessen, B.E.; Kalkman, D.N.; Aquino, M.; Sorrentino, S.; Giustino, G.; Farhan, S.; Vogel, B.; Sartori, S.; Montalescot, G.; et al. Residual Inflammatory Risk in Patients with Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. *J. Am. Coll. Cardiol.* 2019, 73, 2401–2409. [CrossRef]

18. Lattuca, B.; Sy, V.; Nguyen, L.S.; Bernard, M.; Zeitouni, M.; Overchouk, P.; Yan, Y.; Hammoudi, N.; Ceccaldi, A.; Collet, J.; et al. Copeptin as a prognostic biomarker in acute myocardial infarction. *Int. J. Cardiol.* 2019, 274, 337–341. [CrossRef]

19. Camaro, C.; Damman, P. Antithrombotic PreTreatment and Invasive Strategies in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. *J. Clin. Med.* 2020, 9, 2578. [CrossRef]

20. Parodi, G.; Valenti, R.; Bellandi, B.; Migliorini, A.; Marcucci, R.; Comito, V.; Carrabba, N.; Santini, A.; Gensini, G.F.; Abbate, R.; et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. *J. Am. Coll. Cardiol.* 2013, 61, 1601–1606. [CrossRef]

21. Montalescot, G.; Bolognese, L.; Dudek, D.; Goldstein, P.; Hamm, C.; Tanguay, J.; Ten Berg, J.M.; Miller, D.L.; Costigan, T.M.; Goedicke, J.; et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. *N. Engl. J. Med.* 2013, 369, 999–1010. [CrossRef] [PubMed]

22. Montalescot, G.; Collet, J.-P.; Ecollan, P.; Bolognese, L.; Ten Berg, J.; Dudek, D.; Hamm, C.; Widimsky, P.; Tanguay, J.; Goldstein, P.; et al. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: The ACCOAST-PCI study. *J. Am. Coll. Cardiol.* 2014, 64, 2563–2571. [CrossRef] [PubMed]

23. Silvain, J.; Rakowski, T.; Lattuca, B.; Liu, Z.; Bolognese, L.; Goldstein, P.; Hamm, C.; Tanguay, J.; ten Berg, J.; Widimsky, P.; et al. Interval from Initiation of Prasugrel to Coronary Angiography in Patients with Non-ST-Segment Elevation Myocardial Infarction. *J. Am. Coll. Cardiol.* 2019, 73, 906–914. [CrossRef] [PubMed]

24. Wallentin, L.; Becker, R.C.; Budaj, A.; Cannon, C.P.; Emanuelsson, H.; Held, C.; Horrow, J.; Husted, S.; James, S.; Katus, H.; et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N. Engl. J. Med.* 2009, 361, 1045–1057. [CrossRef]

25. Lindholm, D.; Varenhorst, C.; Cannon, C.P.; Harrington, R.A.; Himmelmann, A.; Maya, J.; Husted, S.; Steg, P.G.; Cornel, J.; Storey, R.F.; et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: Results from the PLATO trial. *Eur. Heart J.* 2014, 35, 2083–2093. [CrossRef]

26. Schüppe, S.; Neumann, F.-J.; Menichelli, M.; Mayer, K.; Bernlochner, I.; Wöhrle, J.; Richardt, G.; Liebetrau, C.; Witzenbihler, B.; Antoniucci, D.; et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. *N. Engl. J. Med.* 2019, 381, 1524–1534. [CrossRef]
27. Tarantini, G.; Mojoli, M.; Varbella, F.; Caporale, R.; Rigattieri, S.; Andò, G.; Cirillo, P.; Pierini, S.; Santarelli, A.; Sganzerla, P.; et al. Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome. *J. Am. Coll. Cardiol.* 2020. [CrossRef]

28. Almendro-Delia, M.; Gonzalez-Torres, L.; Garcia-Alcantara, Á.; Reina-Toral, A.; Sánchez, J.A.A.; Yañez, J.C.R.; Hidalgo-Urbano, R.; Rubira, J.C.G.; ARIAM-Andalucía Group. Prognostic impact of clopidogrel pretreatment in patients with acute coronary syndrome managed invasively. *Am. J. Cardiol.* 2015, 115, 1019–1026. [CrossRef]

29. Dworeck, C.; Redfors, B.; Angerås, O.; Haraldsson, I.; Odenstedt, J.; Ioanes, D.; Petursson, P.; Völz, S.; Persson, J.; Koul, S.; et al. Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndromes with Outcomes. *JAMA Netw. Open* 2020, 3, e2018735. [CrossRef]

30. Wiviott, S.D.; Braunwald, E.; McCabe, C.H.; Montalescot, G.; Ruzyllo, W.; Gottlieb, S.; Neumann, F.; Ardissino, D.; de Servi, S.; Murphy, S.A.; et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N. Engl. J. Med.* 2007, 357, 2001–2015. [CrossRef]

31. Menichelli, M.; Neumann, F.-J.; Ndrepepa, G.; Mayer, K.; Wöhrle, J.; Bernlochner, I.; Richardt, G.; Witzenbichler, B.; Sibbing, D.; Gewalt, S.; et al. Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes: Results From a Randomized Trial. *Ann. Intern. Med.* 2020, 173, 436–444. [CrossRef]

32. Schnorbus, B.; Daiber, A.; Kurk, K.; Warnke, S.; Koenig, J.; Lackner, K.J.; Münzel, T.; Gori, T. Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: A randomized, blinded, parallel study. *Eur. Heart J.* 2020, 41, 3144–3152. [CrossRef]

33. Palmerini, T.; Benedetto, U.; Biondi-Zoccai, G.; Della Riva, D.; Bacchi-Reggiani, L.; Smits, P.C.; Vlaeohlannis, G.J.; Jensen, L.O.; Christiansen, E.H.; Bereneci, K.; et al. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. *J. Am. Coll. Cardiol.* 2015, 65, 2496–2507. [CrossRef]

34. Giustino, G.; Baber, U.; Sartori, S.; Mehran, R.; Mastorís, I.; Kini, A.S.; Sharma, S.K.; Pocock, S.J.; Dangas, G.D. Duration of dual antiplatelet therapy after drug-eluting stent implantation: A systematic review and meta-analysis of randomized controlled trials. *J. Am. Coll. Cardiol.* 2015, 65, 1298–1310. [CrossRef] [PubMed]

35. Guedeney, P.; Giustino, G.; Sorrentino, S.; Claessen, B.E.; Camaj, A.; Kalkman, D.N.; Vogel, B.; Sartori, S.; de Rosa, S.; Baber, U.; et al. Efficacy and safety of alirocumab and evolocumab: A systematic review and meta-analysis of randomized controlled trials. *Eur. Heart J.* 2019. [CrossRef] [PubMed]

36. Guedeney, P.; Sorrentino, S.; Giustino, G.; Chapelle, C.; Laporte, S.; Claessen, B.E.; Ollier, E.; Camaj, A.; Kalkman, D.N.; Vogel, B.; et al. Indirect Comparison of the Efficacy and Safety of Alirocumab and Evolocumab: A Systematic Review and Network Meta-Analysis. *Eur. Heart J. Cardiovasc. Pharmacother.* 2020. [CrossRef] [PubMed]

37. Guedeney, P.; Baber, U.; Claessen, B.; Aquino, M.; Camaj, A.; Sorrentino, S.; Vogel, B.; Farhan, S.; Faggioni, M.; Chandrasekhar, J.; et al. Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry. *Am. Heart J.* 2019, 207, 10–18. [CrossRef] [PubMed]

38. Guedeney, P.; Claessen, B.E.; Baber, U.; Camaj, A.; Sorrentino, S.; Aquino, M.; Blum, M.; Chandiramani, R.; Goel, R.; Elsayed, S.; et al. Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. *Am. J. Cardiol.* 2019, 123, 1788–1795. [CrossRef] [PubMed]

39. Capodanno, D.; Bhatt, D.L.; Eikelboom, J.W.; Fox, K.A.A.; Geisler, T.; Gibson, C.M.; Gonzalez-Juanatey, J.R.; James, S.; Lopes, R.D.; Mehran, R.; et al. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. *Nat. Rev. Cardiol.* 2020. [CrossRef] [PubMed]

40. Armstrong, P.C.J.; Leadbeater, P.D.; Chan, M.V.; Kirkby, N.S.; Jakubowski, J.A.; Mitchell, J.A.; Warner, T.D. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. *J. Thromb. Haemost.* 2011, 9, 552–561. [CrossRef] [PubMed]
41. Vranckx, P.; Valgimigli, M.; Jüni, P.; Hamm, C.; Steg, P.G.; Heg, D.; van Es, G.A.; McFadden, E.P.; Onuma, Y.; van Meijeren, C.; et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: A multicentre, open-label, randomised superiority trial. *Lancet* 2018, 392, 940–949. [PubMed]

42. Guedeney, P.; Montalescot, G. GLOBAL LEADERS: Looking now at the bigger picture. *EuroIntervention* 2019, 15, e1030–e1032. [CrossRef]

43. Hahn, J.-Y.; Song, Y.B.; Oh, J.-H.; Chun, W.J.; Park, Y.H.; Jang, W.J.; Im, E.; Jeong, J.; Cho, B.R.; Oh, S.K.; et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. *JAMA* 2019, 321, 2428–2437. [CrossRef] [PubMed]

44. Watanabe, H.; Domei, T.; Morimoto, T.; Natsuaki, M.; Shiomi, H.; Toyota, T.; Ohya, M.; Suwa, S.; Takagi, K.; Nanasato, M.; et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. *JAMA* 2019, 321, 2414–2427. [CrossRef] [PubMed]

45. Mehran, R.; Baber, U.; Sharma, S.K.; Cohen, D.J.; Angiolillo, D.J.; Briguori, C.; Cha, J.Y.; Collier, T.; Dangas, G.; Dudek, D.; et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. *N. Engl. J. Med.* 2019, 381, 1621–1631. [CrossRef]

46. Guedeney, P.; Mesnier, J.; Sorrentino, S.; Abcha, F.; Zeitouni, M.; Lattuca, B.; Silvain, J.; de Rosa, S.; Indolfi, C.; Collet, J.; et al. Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J. Clin. Med.* 2020, 9, 680. [CrossRef]

47. Tersalvi, G.; Biasco, L.; Cioffi, G.M.; Pedrazzini, G. Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective. *J. Clin. Med.* 2020, 9, 2064. [CrossRef]

48. Claassens, D.M.; Sibbing, D. De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature. *J. Clin. Med.* 2020, 9, 2983. [CrossRef] [PubMed]

49. Sibbing, D.; Aradi, D.; Jacobshagen, C.; Gross, L.; Trenk, D.; Geisler, T.; Orban, M.; Hadamitzky, M.; Merkely, B.; Kiss, R.G.; et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): A randomised, open-label, multicentre trial. *Lancet* 2017, 390, 1747–1757. [CrossRef]

50. Claassens, D.M.F.; Vos, G.J.A.; Bergmeijer, T.O.; Hermanides, R.S.; van’t Hof, A.W.J.; van der Harst, P.; Barbato, E.; Morisco, C.; Tjon Joe Gin, R.M.; Asselbergs, F.W.; et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. *N. Engl. J. Med.* 2019, 381, 1621–1631. [CrossRef]

51. Fontana, P.; Roffi, M.; Reny, J.-L. Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s. *J. Clin. Med.* 2020, 9, 194. [CrossRef] [PubMed]

52. Chan Pin Yin, D.; Azzahhafi, J.; James, S. Risk Assessment Using Risk Scores in Patients with Acute Coronary Syndrome. *J. Clin. Med.* 2020, 9, 3039. [CrossRef] [PubMed]

53. Mauri, L.; Kereiakes, D.J.; Yeh, R.W.; Driscoll-Shempp, P.; Cutlip, D.E.; Steg, P.G.; Normand, S.T.; Braunwald, E.; Wiviott, S.D.; Cohen, D.J.; et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. *N. Engl. J. Med.* 2014, 371, 2151–2166. [CrossRef]

54. Bonaca, M.P.; Bhatt, D.L.; Cohen, M.; Storey, R.F.; Jensen, E.C.; Magnani, G.; Bansilal, S.; Fish, M.P.; Im, K.; et al. Long-term use of ticagrelor in patients with prior myocardial infarction. *N. Engl. J. Med.* 2015, 372, 1791–1800. [CrossRef] [PubMed]

55. Eikelboom, J.W.; Connolly, S.J.; Bosch, J.; Dagenais, G.R.; Hart, R.G.; Shestakovska, O.; Diaz, R.; Alings, M.; Lonn, E.M.; Anand, S.S.; et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. *N. Engl. J. Med.* 2017, 377, 1319–1330. [CrossRef]

56. Urban, P.; Mehran, R.; Colleran, R.; Angiolillo, D.J.; Byrne, R.A.; Capodanno, D.; Cuisset, T.; Cutlip, D.; Eerdmanx, P.; Eikelboom, J.; et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: A consensus document from the Academic Research Consortium for High Bleeding Risk. *Eur. Heart J.* 2019, 40, 2632–2653. [CrossRef] [PubMed]
57. Cao, D.; Mehran, R.; Dangas, G.; Baber, U.; Sartori, S.; Chandiramani, R.; Stefanini, G.G.; Angiolillo, D.J.; Capodanno, D.; Urban, P.; et al. Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. *J. Am. Coll. Cardiol.* 2020, 75, 2711–2722. [CrossRef]

58. Dewilde, W.J.M.; Oirbans, T.; Verheugt, F.W.A.; Kelder, J.C.; de Smet, B.J.G.L.; Herrman, J.; Adriaenssens, T.; Vrolix, M.; Heestermans, A.A.C.M.; Vis, M.M.; et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. *Lancet* 2013, 381, 1107–1115. [CrossRef]

59. Gibson, C.M.; Mehran, R.; Bode, C.; Halperin, J.; Verheugt, F.W.; Wildgoose, P.; Birmingham, M.; Ianus, J.; Burton, P.; van Eickels, M.; et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. *N. Engl. J. Med.* 2016, 375, 2423–2434. [CrossRef]

60. Cannon, C.P.; Bhatt, D.L.; Oldgren, J.; Lip, G.Y.H.; Ellis, S.G.; Kimura, T.; Maeng, M.; Merkely, B.; Zeymer, U.; Gropper, S.; et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. *N. Engl. J. Med.* 2017, 377, 1513–1524. [CrossRef]

61. Lopes, R.D.; Heizer, G.; Aronson, R.; Vora, A.N.; Massaro, T.; Mehran, R.; Goodman, S.G.; Windecker, S.; Darius, H.; Li, J.; et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. *N. Engl. J. Med.* 2019, 380, 1509–1524. [CrossRef] [PubMed]

62. Vranckx, P.; Valgimigli, M.; Eckardt, L.; Tijsen, J.; Lewalter, T.; Gargiulo, G.; Batushkin, V.; Campo, G.; Lysak, Z.; Vakaliuk, I.; et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial. *Lancet* 2019, 394, 1335–1343. [CrossRef]

63. Bor, W.; Gorog, D.A. Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome. *J. Clin. Med.* 2020, 9, 2020. [CrossRef]

64. Zwart, B.; Parker, W.A.E.; Storey, R.F. New Antithrombotic Drugs in Acute Coronary Syndrome. *J. Clin. Med.* 2020, 9, 2059. [CrossRef]

65. Limbruno, U.; De Sensi, F.; Cresti, A.; Picchi, A.; Lena, F.; De Caterina, R. Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome-Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant... Or, Rather, Temporary Dual Antiplatelet Therapy? *J. Clin. Med.* 2020, 9, 2673. [CrossRef] [PubMed]

66. Gargiulo, G.; Goette, A.; Tijsen, J.; Eckardt, L.; Lewalter, T.; Vranckx, P.; Valgimigli, M. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. *Eur. Heart J.* 2019, 40, 3757–3767. [PubMed]

67. Yasuda, S.; Kaikita, K.; Akao, M.; Ako, J.; Matoba, T.; Nakamura, M.; Miyauuchi, K.; Hagiwara, N.; Kimura, K.; Hirayama, A.; et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. *N. Engl. J. Med.* 2019, 381, 1103–1113. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).